NCT02617784View on ClinicalTrials.gov

A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

June 30, 2002

Study Completion Date

June 30, 2002

Conditions
End Stage Renal Disease
Interventions
DRUG

Oseltamivir

Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.

Trial Locations (1)

8011

Christchurch

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02617784 - A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD) | Biotech Hunter | Biotech Hunter